Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Emarjola, Bako"'
Autor:
Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Zev Wainberg, Elena Elez, Javier Rodriguez, Marwan Fakih, Fortunato Ciardiello, Kapil Saxena, Kojiro Kobayashi, Emarjola Bako, Yasuyuki Okuda, Gerold Meinhardt, Axel Grothey, Salvatore Siena, DESTINY-CRC01 investigators
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prio
Externí odkaz:
https://doaj.org/article/b78d3fdfa83149b6a91ce6f79897ff81
Autor:
Javier, Cortés, Sung-Bae, Kim, Wei-Pang, Chung, Seock-Ah, Im, Yeon Hee, Park, Roberto, Hegg, Min Hwan, Kim, Ling-Ming, Tseng, Vanessa, Petry, Chi-Feng, Chung, Hiroji, Iwata, Erika, Hamilton, Giuseppe, Curigliano, Binghe, Xu, Chiun-Sheng, Huang, Jee Hyun, Kim, Joanne W Y, Chiu, Jose Luiz, Pedrini, Caleb, Lee, Yali, Liu, Jillian, Cathcart, Emarjola, Bako, Sunil, Verma, Sara A, Hurvitz, Gail, Wright
Publikováno v:
New England Journal of Medicine. 386:1143-1154
Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer whose disease progresses after treatment with a combination of anti-HER2 antibodies and a taxa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b546e51ec290c6b7ea098e477d903539
https://doi.org/10.1056/nejmoa2115022
https://doi.org/10.1056/nejmoa2115022
Autor:
Erika P. Hamilton, Vanessa PETRY HELENA Bragaia, Winnie Yeo, Sung-Bae Kim, Giampaolo Bianchini, Toshinari Yamashita, Kan Yonemori, Kenichi Inoue, Giuseppe Curigliano, Sara A. Hurvitz, Javier Cortes, Hiroji Iwata, Jillian Cathcart, Yali Liu, Caleb C. Lee, Emarjola Bako, Rachel Kim, Seock-Ah Im
Publikováno v:
Journal of Clinical Oncology. 40:1000-1000
1000 Background: In the DESTINY-Breast03 (NCT03529110) primary analysis (data cutoff [DCO], May 21, 2021), T-DXd showed superiority over T-DM1 in pts with HER2+ mBC, with a significant improvement of progression-free survival by blinded independent c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4367e24a34e621b838f7773aea2bd23e
https://doi.org/10.1200/jco.2022.40.16_suppl.1000
https://doi.org/10.1200/jco.2022.40.16_suppl.1000
Autor:
S-B Kim, B H Xu, Erika Hamilton, Sara A. Hurvitz, H. Iwata, Emarjola Bako, C-F. Chung, W-P. Chung, Young-Ae Park, Sunil Verma, L-M Tseng, V. Petry, J. Cortés, Min Kim, Caleb Lee, J. Cathcart, Roberto Hegg, S-A. Im, Yali Liu, Giuseppe Curigliano
Publikováno v:
Annals of Oncology. 32:S1287-S1288
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41449928a607678431747caf8d8d965b
https://doi.org/10.1016/j.annonc.2021.08.2087
https://doi.org/10.1016/j.annonc.2021.08.2087
Autor:
Elena Elez, Taito Esaki, Destiny-Crc investigators, Fortunato Ciardiello, Kanwal Pratap Singh Raghav, Fotios Loupakis, Takayuki Yoshino, Eriko Yamamoto, Tomohiro Nishina, Kapil Saxena, Maria Di Bartolomeo, Javier Rodríguez, Axel Grothey, Yasuyuki Okuda, Hisato Kawakami, Zev A. Wainberg, Andrea Sartore-Bianchi, Salvatore Siena, Emarjola Bako, Javad Shahidi, Marwan Fakih, Kensei Yamaguchi, Toshiki Masuishi, Ki Y Chung, Yoshito Komatsu
Summary Background HER2 amplification has been identified in 2–3% of patients with colorectal cancer, although there are currently no approved HER2-targeted therapies for colorectal cancer. We aimed to study the antitumour activity and safety of tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c4b3fdedcfcda48de0a082e048db43f
http://hdl.handle.net/11591/452991
http://hdl.handle.net/11591/452991
Autor:
Sara Hurvitz, Sung-Bae Kim, Wei-Pang Chung, Seock-Ah Im, Yeon Hee Park, Roberto Hegg, Min-Hwan Kim, Ling-Ming Tseng, Vanessa Petry, Chi-Feng Chung, Hiroji Iwata, Erika Hamilton, Giuseppe Curigliano, Binghe Xu, Caleb Lee, Yali Liu, Jillian Cathcart, Emarjola Bako, Sunil Verma, Javier Cortés
Publikováno v:
Cancer Research. 82:GS3-01
Background: T-DXd is a HER2-targeting antibody-drug conjugate approved for the treatment of pts with advanced HER2+ mBC based on the DESTINY-Breast01 study (NCT03248492). DESTINY-Breast03 (NCT03529110) isa randomized, multicenter, open-label, phase 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8eb1c465adc60fde1e19040155ac463
https://doi.org/10.1158/1538-7445.sabcs21-gs3-01
https://doi.org/10.1158/1538-7445.sabcs21-gs3-01
Autor:
Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Pratap Singh Raghav, Toshiki Masuishi, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Zev A. Wainberg, Elena Elez, Javier Rodriguez, Marwan Fakih, Fortunato Ciardiello, Kapil Saxena, Kojiro Kobayashi, Emarjola Bako, Yasuyuki Okuda, Gerold Meinhardt, Axel Grothey, Salvatore Siena
Publikováno v:
Journal of Clinical Oncology. 40:119-119
119 Background: T-DXd is an antibody-drug conjugate of a humanized anti-HER2 antibody bound to a topoisomerase I inhibitor by a cleavable linker. The primary analysis of DESTINY-CRC01 (DS8201-A-J203; NCT03384940), a phase 2, open-label, multicenter s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4790fba7f920a57519e0c2d0a18835b
https://doi.org/10.1200/jco.2022.40.4_suppl.119
https://doi.org/10.1200/jco.2022.40.4_suppl.119
Autor:
Rosine Guimbaud, Tae Won Kim, Jeanne Tie, G. Meinhardt, Joan Maurel, Marc Van den Eynde, Takayuki Yoshino, Emarjola Bako, Salvatore Siena, Ian Chau, Kanwal Pratap Singh Raghav, Kun-Huei Yeh, Daniel Barrios, Kojiro Kobayashi, Mehreteab Aregay
Publikováno v:
Journal of Clinical Oncology. 40:TPS224-TPS224
TPS3620 Background: Trastuzumab deruxtecan (T-DXd) is an antibody–drug conjugate consisting of an anti-HER2 antibody (trastuzumab) linked to a potent topoisomerase I inhibitor (DXd). T-DXd has been approved to treat HER2-positive metastatic breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0a816e03736281edcce15735f80fdd5
https://doi.org/10.1200/jco.2022.40.4_suppl.tps224
https://doi.org/10.1200/jco.2022.40.4_suppl.tps224
Autor:
Takayuki Yoshino, Hisato Kawakami, Kensei Yamaguchi, Toshiki Masuishi, Kapil Saxena, Fotios Loupakis, Kojiro Kobayashi, Elena Elez, Emarjola Bako, Javier Rodríguez, Tomohiro Nishina, G. Meinhardt, Fortunato Ciardiello, Maria Di Bartolomeo, Marwan Fakih, Axel Grothey, Kanwal Pratap Singh Raghav, Zev A. Wainberg, Yasuyuki Okuda, Salvatore Siena
Publikováno v:
Journal of Clinical Oncology. 39:3505-3505
3505 Background: T-DXd is an antibody–drug conjugate of a humanized anti-HER2 antibody bound to a topoisomerase I inhibitor by a cleavable linker. The primary analysis of DESTINY-CRC01 (DS8201-A-J203; NCT03384940), a phase 2, open-label, multicente
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1607da954baf8006d40ef8b12ccdae4f
https://doi.org/10.1200/jco.2021.39.15_suppl.3505
https://doi.org/10.1200/jco.2021.39.15_suppl.3505
Autor:
Elena Elez, Salvatore Siena, Kazuhiko Kobayashi, Fortunato Ciardiello, Marwan Fakih, Kensei Yamaguchi, Takayuki Yoshino, J. Rodriguez, Kapil Saxena, Kanwal Pratap Singh Raghav, Tomohiro Nishina, Hisato Kawakami, Toshiki Masuishi, Emarjola Bako, M. Di Bartolomeo, Yasuyuki Okuda, A. Grothey, Fotios Loupakis, Eriko Yamamoto
Publikováno v:
Annals of Oncology. 31:S1275
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7b62c8451641583ebd2655b5c3f9d9a
https://doi.org/10.1016/j.annonc.2020.10.104
https://doi.org/10.1016/j.annonc.2020.10.104